Table 2.
XPNPEP2 C-2399A Variant Genotype and Allele Frequencies by Gender and ACE Inhibitor-Associated Angioedema Case-Control Status
| XPNPEP2 allele frequency | Patient Type |
|
|---|---|---|
| Control | Case | |
| Female | ||
| All | n=181 | n=93 |
| C/C, n (%) | 116 (64.1) | 56 (60.2) |
| C/A, n (%) | 53 (29.3) | 32 (34.4) |
| A/A, n (%) | 12 (6.6) | 5 (5.4) |
| OR (95% CI) | 1.18 (0.7-2.0) | |
| Blacks | n=84 | n=51 |
| C/C, n (%) | 55 (65.5) | 29 (56.9) |
| C/A, n (%) | 24 (28.6) | 19 (37.3) |
| A/A, n (%) | 5 (6.0) | 3 (5.9) |
| OR (95% CI) | 1.44 (0.7-2.9) | |
| Whites | n=97 | n=42 |
| C/C, n (%) | 61 (62.9) | 27 (64.3) |
| C/A, n (%) | 29 (29.9) | 13 (31.0) |
| A/A, n (%) | 7 (7.2) | 2 (4.8) |
| OR (95% CI) | 0.94 (0.4-2.0) | |
| Male | ||
| All | n=185 | n=71 |
| C/, n (%) | 153 (82.7) | 52 (73.2) |
| A/, n (%) | 32 (17.3) | 19 (26.8) |
| OR (95% CI) | 1.75 (0.9-3.3) | |
| Blacks | n=83 | n=32 |
| C/, n (%) | 72 (86.7) | 22 (68.8) |
| A/, n (%) | 11 (13.3) | 10 (31.3) |
| OR (95% CI) | 2.98 (1.1-7.9) | |
| Whites | n=102 | n=39 |
| C/, n (%) | 81 (79.4) | 30 (76.9) |
| A/, n (%) | 21 (20.6) | 9 (23.1) |
| OR (95% CI) | 1.16 (0.5-2.8) | |
Odds ratios (OR) and 95% confidence intervals (CIs) were calculated for C-2399A A/A + C/A vs C/C (reference) or A/ vs C/ (reference).